header image

Page 60«..1020..59606162..7080..»

Archive for Pet Stem Cell Therapy

Hoof Trimming to Improve Structure and Function – TheHorse.com

The mechanical forces of the 60:40 and 70:30 ratios Bowker sees put pressure on the coffin joint, which eventually leads to navicular disease, he explained (see #5 in the sidebar). Everyone knows this and understands some of the biomechanical issues with this type of foot, but few try to aggressively correct the problem, he told The Horse. Many foot professionals say that such feet are not correctable, or they are only manageable. With this long toe-underrun heel foot, the already-long toe continues to get longer. I mean the actual coffin bone begins to get longer: Its conformation is gradually changing.

As the coffin bone gets longer, the vasculature beneath it must change at the expense of the back part of the foot and the frog; basically, the expanded toe area demands more of the foots blood supply, routing it away from the back of the hoof, which he said is detrimental for the hoof and its overall long-term health.

Of all these husbandry practices, the long-toe, underrun heel is probably the worst one that will give rise to navicular and will definitely make any bout of laminitis much worse, Bowker told The Horse. With a long-toe, underrun heel, the tissues supporting and surrounding the coffin bone become compromised and the distal (bottom) end of the coffin bone gets less and less support and becomes thinner and thinner along the edges, especially the lateral (away from the midline) side of the foot. These changes will often result in pedal osteitis; many people have heard of this problem.

When theres a bout of laminitis (and added) toe pressure through some rotation at the toe, the bone cannot support the weight of the horse with this peripheral thinning of the bone, and the coffin bone becomes crushed, he added. Thats the end of the horse!

We are setting the horse up for failure by having a long toe with our trimming methods, regardless of whether the horse is shod or barefoot, he said.

Bowker trims to shorten the toe and promote caudal (toward the rear) migration of the heels to bring the central sulcus (the cleft between the heels) back to the sole of the foot so it makes light contact with the ground. He said trimming with these goals can improve the foots health and get the ratio to approach 40:60allowing the back part of the foot to enlarge and return to its robust health.

Our (industry standard) trimming is such that very few people trim inside the white line, he said, and not only does the hoof wall get longer, the coffin bone gets longerthis remodeling changes the conformation of the bone and its bone density. My belief is that we can correct that, but its going to take time and effort.

See the original post here:
Hoof Trimming to Improve Structure and Function - TheHorse.com

Stem Cell Therapy & Your Pet – CriticalCareDVM

Medical doctors have used stem cell therapy to help treat a myriad of orthopedic conditions in people. Veterinarians have similarly used stem cell therapy, but were still learning about the benefits and risks of this treatment modality in pets. In this weeks post I share some information about stem cell therapy to increase awareness of this novel treatment. Happy reading!

Regenerative medicine also called orthobiologics is a relatively new way of treating certain health conditions, typically involving the musculoskeletal system. Using various techniques, veterinarians can make and introduce a solution with a high concentration of substances like growth factors and anti-inflammatory chemicals into a part of the body that tends to heal poorly or slowly. Many folks hear or read the term regenerative medicine and immediately think of cloning or growing new tissues in a laboratory. Thats not regenerative medicine.

Using stem cells is a form of regenerative medicine. There are two types of stem cells made by mammals: those of embryonic origin and those from fully matured (aka adult) tissue. There is a key difference between the two types. Embryonic stem cells differentiate into any cell cell this characteristic is called totipotency. In contrast, adult stem cells differentiate into more than one cell type but not all of them this characteristic is called multipotency. Under normal conditions, stem cells divide and differentiate to replace dead cells to facilitate tissue renewal.

In veterinary medicine, we use adult-derived stem cells. These cells are also called mesenchymal stem cells, and they exist naturally in muscle, fat, cartilage, bone, and bone marrow, as well as in the tissues that make up the circulatory, urinary, and reproductive systems. The International Society for Cellular Therapy established criteria for a cell to qualify as a therapeutic mesenchymal stem cell, including:

We preferentially use the term mesenchymal stromal cells (MSC) when referencing stem cells harvested from bone marrow and fat. Why? Because cells from these locations dont possess all of the characteristics of stem cells described above. Nevertheless, MSCs are the most common types used in veterinary medicine.

Mesenchymal stromal cells are categorized based on the animal from which they where harvested, specifically:

Research suggests MSCs may be used for a variety of patient benefits, particularly:

In veterinary medicine, doctors most commonly use MSCs for orthopedic issues like osteoarthritis, ligament injuries (i.e.: cranial cruciate ligament rupture), and tendon problems (i.e.: supraspinatus tendinopathy). There are also published and/or ongoing clinical trials using MSCs for non-orthopedic conditions, including:

Pet owners should remember stem cell therapy is not a therapeutic panacea. For pets to reap maximal benefits of stem cell therapy, veterinarians must have a definitive diagnosis and they need to be able to treat the underlying health condition(s). Stem cell therapy does not replace conventional therapeutic interventions it augments them.

Veterinarians will need to sedate or anesthetize pets to procure mesenchymal stromal cells from adipose (fat) tissue and bone marrow. They can obtain a sample of bone marrow from the humerus (upper arm bone), tibia (shin), ilium (part of the hip), or femur (upper leg bone). Veterinarians harvest adipose tissue from either the axilla (armpit) or inguinal region (groin).

Once harvested, veterinarians can either submit cells for culturing or they can process them immediately for administration. Culturing is a technique that allows one to develop an expanded population of homogeneous (very similar) MSCs. This technique is performed at specialized laboratories. In contrast, veterinarians immediately process non-cultured samples using a specific type of on-site centrifuge. Processing non-cultured cells are concentrates them, but doesnt result in population expansion.

Once processed, the MSCs are injected into the target tissue. This typically requires sedation or anesthesia. Administration is an outpatient procedure, and veterinarians usually discharge patients with a short course of pain medication. Those receiving therapy for orthopedic conditions usually participate in rehabilitation under the guidance of a board-certified veterinary sports medicine and rehabilitation specialist or certified canine rehabilitation practitioner (CCRP).

Stem cell therapy for cats and dogs is growing in popularity due to documented success in human medicine. There are many health conditions that may benefit from MSC therapy in veterinary medicine, and weve had some positive improvements in certain diseases. Nevertheless, we still have a lot to learn about the role of regenerative medicine in veterinary medicine.

To find a board-certified veterinary surgeon, please visit the American College of Veterinary Surgeons.

To find a board-certified veterinary sports medicine and rehabilitation specialist, please visit the American College of Veterinary Sports Medicine and Rehabilitation.

To find a certified canine rehabilitation practitioner, please click here.

Wishing you wet-nosed kisses,

CriticalCareDVM

See original here:
Stem Cell Therapy & Your Pet - CriticalCareDVM

Gallant Pet – Stem Cells for Dogs – Shark Tank Blog

Aaron Hirschhorn started Gallant Pet because he loves his dog. We all do, and he wanted to make life easier for his elderly dog who was suffering from arthritis. Since Aaron had relief from chronic back pain from regenerative stem cell therapy, he knew it would work for his dog too.

He had experience with a pet related called DogVacay, a peer to peer dog sitting website. The site was acquired by Rover, the monster of that industry. Gallant Pet is a whole different ball game though there are far more moving parts. Stem cell therapy helps with a variety of injuries in pets from dry eye to arthritis to help heal injuries. In order to inject stem cells, you need to have them in the first place.

What Gallant Pet does is work with veterinarians. When a vet spays or neuters a dog, they retain the reproductive organs which contain stem cells. They ship them to Gallant's lab and Gallant stores them in a cryofreezer in their lab. When your dog needs regenerative therapy in the future, you call the lab and they ship the cells to your vet for treatment.

Stem cell therapy is a proven method for dogs and humans. The methodology for treatment is essentially the same, the only difference is the species being treated. Veterinarian bills can get quite pricey for serious conditions on dogs and ongoing treatments. With stem cell therapy, depending on the injury, results can be much better and far less expensive. It's a good business. Aaron probably wants a Shark to add to the $11 million in venture funds he's already raised.

I LOVE my dog. I've loved every dog that's been in my life. My current dog, Zoey (pictured above), is a three and a half year old American Bulldog. She's seventy pounds of pure mayhem, but she's very loyal, obedient and sweet. She's still young and in very good health. We adopted her at two years old, so we missed out on harvesting stem cells for her. I pray we don't need them.

My previous dog, Bailey, passed in June, 2017 one month shy of her 16th birthday. She was a healthy dog until her final two years or so that's when the arthritis kicked in. She was a larger dog about 80 pounds and she had a tough time getting up and moving around at the end. If stem cell therapy would have helped her, I'd have gladly spent the money. Unfortunately, harvesting stem cells for dogs wasn't a thing when she was born. Like Aaron, I know people will do anything for their dogs. That's why I know his business will succeed. I am in.

It's no coincidence that Gallant Pet is pitching when Anne Wojcicki is on the panel as a Guest Shark. The recent influx of Guest Sharks means you see businesses pitching to the guest's niche. Tonight is no exception. While he's already raised $11 million, he's going to need more cash to make Gallant Pet a big business. There's a lot of outreach and education to veterinarians and the dog loving public that needs to be done.

As for which Shark bids, Wojcicki is the obvious target. She's in that online/medical/sample collection niche. 23AndMe collects and analyzes samples, so there's some synergy there. As for the other Sharks, Daymond is a dog lover, but this is a little out of his wheel house. Lori probably won't get on board, neither will Kevin, unless it's a token Kevin bid to spice things up. Mark may get involved if the numbers are good and we could see him team up with Wojcicki. I predict a deal.

More here:
Gallant Pet - Stem Cells for Dogs - Shark Tank Blog

Overview of Animal Medication Market with the Productivity Data Analysis and Future Forecast According to Leading Companies Bayer HealthCare AG,…

The research report named as Animal Medication Market has been recently announced by Research N Reports which provides a clear understanding of the subject matter. This report has been made using primary and secondary research techniques and they are now intended towards collaborating accurate and exact data. Additionally, this report also has the SWOT analysis that determines the external segments that impact the overall market. This highly surveyed statistical report also tries to comprehend the approaches taken by the vendors in the Animal Medication market to provide product differentiation through Porters five forces analysis which is inventive.

Get sample copy of this report:

https://www.researchnreports.com/request_sample.php?id=58970

Leading Companies Bayer HealthCare AG, Boehringer Ingelheim GmbH, Ceva Sante Animale S.A., Dechra Pharmaceuticals PLC, Eli Lilly and Company, Merck Animal Health, Merial, Vetericyn Inc., Vetoquinol SA etc.

Veterinary pharmaceutical producers have begun to use stem cell therapy as animal medicine because of its excellent ability to cure arthritis or animal lesions. Stem cell therapy is a process of injecting stem cells into the animals body to replace damaged body cells. The injected stem cell is not qualified and acquires the property of the cell that needs to be replaced. It is also divided into as many cells as the body needs. It allows treating bone and ligament injuries, kidney and liver diseases and some types of skin diseases.

The essential demographic, geographic, psychographic and behavioral information about the business segments in the Animal Medicine Market is intended to help determine the characteristics that the company must cover to meet business requirements. For the consumer market, the study is also categorized with Market Maker information to better understand who customers are and their behavior and buying patterns.

Significant Features that are Under Offering and Key Highlights of the Reports:

Avail maximum Discount on this report:

https://www.researchnreports.com/ask_for_discount.php?id=58970

Table of Content:

Chapter 1: Animal Medication Market Data Analysis

Chapter 2: Data Analysis

Chapter 3: Recent Government Policy and News

Chapter 4: Animal Medication Market Production Process and Revenue

Chapter 5: Forecast of Production and Supply Demand Market Status

Chapter 6: Animal Medication Market Leading Manufactures

Chapter 7: Productive Marketing Strategy

Continue for TOC

For more information please visit:

https://www.researchnreports.com/enquiry_before_buying.php?id=58970

Contact us and your reports customized according to your needs!

About Research N Report

Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer-driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a soundboard firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cut-throat global competition. Since we excel at business research to help businesses grow, we also offer consulting as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently, we keep evolving as an all-rounder provider of viable information under one roof.

Contact us

Sunny Denis

Sales Manager

Research N Reports

10916, Gold Point Dr, Houston, TX, Pin 77064.

+1-8886316977

Email: sales@researchnreports.com

Website: http://www.researchnreports.com

Follow Us on LinkedIn: https://www.linkedin.com/company/research-n-reports/

See the original post:
Overview of Animal Medication Market with the Productivity Data Analysis and Future Forecast According to Leading Companies Bayer HealthCare AG,...

Canine Stem Cell Therapy Market Expected to Be Valued CAGR 4.2% by 2017 to 2026 – Zebvo

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process.

The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then.

This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

Company Profiles

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption.

The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians. A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs.

Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance.

The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Go here to read the rest:
Canine Stem Cell Therapy Market Expected to Be Valued CAGR 4.2% by 2017 to 2026 - Zebvo

What its like to get laser hair removal as a black woman – Yahoo Lifestyle

Im hairythats just fact, and its something Ive always been aware of. Ill never forget being in summer camp as a kid, wearing shorts every day and becoming very aware that my legs were much hairier than those of the girls around me. Now, Im no longer ashamed of being hairyIve actually come to embrace it. But in the past two decades, Ive gotten very acquainted with epilators, including laser hair removal.

I got my first laser hair removal treatment two years ago. It seemed like everyone was getting it done, but as a black woman, I knew I wasnt everyone. For brown skin, laser hair removal isnt a spur-of-the-moment decision, a process that should be approached through a Groupon or the local nail salon (yes, some nail salons actually perform laser hair removal). For us, the process can be a bit more expensive and tedious, and should be approached with the utmost caution.

Why? Well, lasers target pigment, and due to the high content of melanin in our skin, risks of discoloration and hyper-pigmentation are astronomically higher. So thats why, according to Chris Karavolas, owner of Romeo And Juliette Laser Hair Removal, darker skin requires a completely different laser all together, and operators with much more experience. Darker skin complexions need to be careful because not all centers have the right lasers for dark skin, and even if they do they do, many do not have enough experience in treating dark skin, he says.

When it comes to those specialized lasers, there are two options. Its important to treat with an Nd:YAG laser, such as the Candela GentleYAG or GentleMax Pro, says Anne Chapas, M.D., medical director of Union Square Laser Dermatology in New York City. The wavelength of a YAG laser goes deeper into the skin than a diode laser and is less absorbed by the surrounding skin pigment, so it more successfully treats the stem cells of the hair follicle. Additionally, more treatments may be required than for fairer skin: Expect to receive at least six sessions, Chapas says.

Knowing all these things, I went into laser hair removal with cautious optimism. I chose to treat my Brazilian areayears of improper hair removal had left me with ingrown and severe discoloration, to the point that my wax lady refused to continue treating me because my skin had gotten so irritated. I was sure that I wanted to continue being hair-free down there, so I decided to get laser hair removal on my vagina area. I was nervous heading into my first appointment, so I made sure to ask the aesthetician at Romeo & Juliette in-depth questions about her experience with dark skin, as well as requesting to see photos of previous clients and inquiring about a patch test. Then, it was showtime.

I like to think that I have a pretty high pain tolerance. However, laser removal certainly made me question that belief. I wont lie and say that it didnt hurt. It did. It felt like being snapped, hard, by rubber bands, but it was quick, and the results I saw were almost immediate. I was advised to shave right before the treatment, in order to give the laser immediate access to the hair follicle, and because, well, nobody likes the smell of burning hair. After about 10 minutes, I was sent on my way and advised to come back in another six weeks. Laser hair removal requires a strict schedule and works in conjunction with the hair cycle for optimal results. Every appointment thereafter was just as easy, and now, completely through all six of my sessions, my hair is almost completely gone, with the occasional stubble appearing here and there.

So how do you know if your skin will need one of these specialized lasers? Different ethnicitiesregardless of skin tonereact differently to lasers. Your skin may appear to be a 3 or 4 on the Fitzpatrick scale, but if youre, say, Latin or Asian, it could react to the laser as a 6 would, Dr. Chapas says. So be sure that youre only going to facilities that have operators trained in dermatology, and are skilled enough to differentiate your skin tone.

Here is the original post:
What its like to get laser hair removal as a black woman - Yahoo Lifestyle

Dolly the sheep: 20yrs on, what’s the state of play in cloning? – Spring Hill Insider

Dolly the sheep: 20yrs on, whats the state of play in cloning? On February 22, 1997 Dolly the sheep, the first mammal successfully cloned from an adult cell, was revealed at her pen in Edinburgh, Scotland, sparking a huge moral furore. So 20 years on, how has cloning developed and are we any closer to human cloning?

Dolly a game-changer

The sheep had been cloned through somatic cell nuclear transfer (SCNT) creating a viable embryo from a body cell and an egg cell.

Dolly had proved the impossible that a new creature could be cloned from an adult cell. It also showed that an egg can change cell type, prompting research into whether other factors could be used in the alteration.

Sir Ian Wilmut, who led the research, at a public lecture last year on Dollys legacy that experiments on altering cell type led by Shinya Yamanaka in 2006 are among the most important so far this century.

Yamanaka Dolly as the inspiration behind his discovery of induced pluripotent stem cells (iPS cells), which earned him a Nobel Prize. The Japanese scientist and his team generated stem cells from mature mice fibroblasts cells a breakthrough for transforming bio-research.

Dollys death at just six-and-a-half coupled with the fact she was created using a cell from a six-year-old sheep, gave rise to the assumption that offspring created from an adult cell started life at an age disadvantage and were not truly newborn. However, more recent research debunked this theory by that Dollys cloned siblings reached their ninth birthday in healthy condition.

Professor Kevin Sinclair at the noted that between seven to nine years of age (60 to 70 in human years), the clones showed no long-term detrimental health effects.

Will the woolly mammoth come back to life?

Discussion around cloning the extinct woolly mammoth has been rife for years with of resurrecting the species through cloning.

In 2008, scientists successfully managed to clone a mouse from tissue that had been deep frozen for 16 years. Five years later, a mammoth specimen in Siberia, Russia, oozed what scientists believed was blood, and spurred hopes it may have enough DNA to recreate the mammoth genome.

It appears the optimism has not gone away: last week Harvard scientists their plans to produce a hybrid elephant-mammoth embryo in the near future. It would involve programing mammoth traits into an Asian elephant using gene-editing tool , creating a mammophant a modified elephant as opposed to a mammoth.

The at the University of Edinburgh states, however, that while in theory full mammoth resurrections might be possible, in reality they are extremely unlikely as a suitable surrogate mother is required and viable whole cells are needed.

Cloning & big business

South Korea has led the way in pet cloning with the Biotech Research Foundation offering cloning services for a cost of (95,000) since 2006, using the same technique used to clone Dolly.

The operation has not come without controversy, however, as the companys founder Woo Suk Hwang was convicted of embezzlement and bioethics law violations in May 2006 after it was revealed much of his stem cell research was faked.

Despite the scandal, business has continued with the facility cloning hundreds of dogs as well as cows, pigs and even coyotes since its inception. Last year the company the launch of its military dog program.

Soaam signed a canine cloning license in 2014 with Texas-based company , who previously specialized in equine and livestock cloning. Viagen has used cloning tech to enter the horse market, claiming it can create a foal identical to the elite donor, offering a unique type of insurance to horse owners and breeders.

Meanwhile, plans are underway in China for the worlds largest animal cloning center in Tijanin. Chinese company,partnered with Sooam for the ambitious project with the intention of cloning animals including sniffer and pet dogs, beef cattle and racehorses.

In 2015 the group revealed a 200 million yuan ($31 million) project investment and outlined plans to produce 100,000 cattle embryos a year initially, later increasing to 1 million to combat future food shortages. While the facility was originally earmarked to be in use by the end of 2016, a spokesperson for Boyalife told RT that the factory construction has yet to be completed.

So whats stopping human cloning?

The revelation of Dolly sparked huge political debate, with concerns immediately centered around the possibility of human clones and its ethical implications.

Then-President Bill Clinton instructed Americas National Bioethics Advisory Commission to report on human cloning within 90 days while the president of the European Commission and the directors of UNESCO and issued similar directives. The Vatican called for an outright ban on cloning.

These ethical objections to reproductive cloning, however, are not the sole reason human clones havent been developed: according to researchers, scientific limitations and lack of commercial interest are also factors.

In terms of humans and cloning, scientists currently appear more focused on therapeutic cloning for treating diseases, replicating human embryos to harvest stem cells for medical uses.

In 2013 a human cell was using SCNT in experiments led by reproductive biology specialist, Shoukhrat Mitalipov, sparking hopes that stem cells could be used in the treatment of conditions such as Parkinsons disease and diabetes.

This has yet to be realized but scientists are continuing to stem cell research with the view of developing disease treatments and therapies.

See the original post here:
Dolly the sheep: 20yrs on, what's the state of play in cloning? - Spring Hill Insider

Global Animal Stem Cell Therapy Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Industry PressRelease

The Animal Stem Cell Therapy Market report gives an astonishing source to analyze the Animal Stem Cell Therapy market and other fundamental subtleties identifying with it. The examination uncovers the general evaluation and associated ideas of the Animal Stem Cell Therapy market. The report displays a reasonable scenario of the Animal Stem Cell Therapy market, that links applications, proposals, industry chain structure, and definitions. Likewise, it connects the expansive validity of the Animal Stem Cell Therapy market and configurations to a fundamental precision, experiences, and industry-substantiated estimations of the general Animal Stem Cell Therapy market. Additionally, the examination underlines the huge driving business players (Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel) across the globe with clear affiliation profiles, data of the wide-ranging business, item type, conditions, and courses of action.

The Animal Stem Cell Therapy market report more focuses on top industry leaders and explores all essentials facets of competitive landscape. It explains potent business strategies and approaches, consumption propensity, regulatory policies, recent moves taken by competitors, as well as potential investment opportunities and market threats also. The report emphasis crucial financial details of major manufacturers including year-wise sale, revenue growth, CAGR, production cost analysis, and value chain structure.

Interesting? Apply for a sample report: http://www.intenseresearch.com/market-analysis/global-animal-stem-cell-therapy-market-2019-by.html#request-sample

The manufacturing base, Animal Stem Cell Therapy Industry chain view, raw material cost, labor cost, and downstream buyers analysis is represented. The production and market share by type and application from 2019-2025 are presented in this study. Also, the consumption ratio, gross margin analysis, and import-export statistics are portrayed. The market status and SWOT analysis for different regions and countries are profiled in this report.

Global Animal Stem Cell Therapy Market: Type Outlook:Dogs, Horses, Others

Global Animal Stem Cell Therapy Market: Application Outlook:Veterinary Hospitals, Research Organizations

North America (United States, Canada)Europe (Germany, France, UK, Italy, Russia, Spain)Asia Pacific (China, Japan, Korea, India, Australia, New Zealand)Middle East & Africa (Middle East, Africa)Latin America (Mexico, Brazil, C. America, Chile, Peru, Colombia)

Furthermore, the report provides the core knowledge of the market by analyzing end users consumption tendency, Animal Stem Cell Therapy market driving factors, ever-changing market dynamics, and rising development patterns in the market.

Besides, the report focuses on the leading contenders in the Animal Stem Cell Therapy industry and delivers an all-inclusive analysis considering their market share, production capacity, value chain analysis, size, sales and distribution network, import/export activities, cost structure, and product specification. Due to the changes in world business policies, it is recommended to be always aware of the facts and data about this market.

The study objectives of this report are:

1) To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).2) To understand the structure of the Animal Stem Cell Therapy market by identifying its various sub-segments.3) The marketing strategies, opportunities, and Animal Stem Cell Therapy development factors are explained.4) The competitive landscape structure, market size estimation, recent advancements in the industry are explained.5) The market dynamics, competition, and complete insights will lead to profitable business plans.6) The pricing structure covering the labor cost, raw material cost, capacity, and supply-demand statistics are presented.

The key dynamic factors that are detailed in the report:

Key Market Dynamics: The Global Animal Stem Cell Therapy Market research report details the latest industry trends, growth patterns, and research methodologies. The factors that directly contribute to the growth of the market include the production strategies and methodologies, development platforms, and the product model itself, wherein a small change would result in further changes in the overall report. All of these factors are explained in detail in the research study.

Market Outlook: The report also sheds light on some of the major factors, including R&D, new product launches, M&A, agreements, partnerships, joint ventures, collaborations, and growth of the key industry participants, on a regional and global basis.

Major Features: The report provides a thorough analysis of some of the significant factors, which include cost, capacity, capacity utilization rate, production, revenue, production rate, consumption, import/export, supply/demand, gross, market share, CAGR, and gross margin. Besides, the report provides a comprehensive study of the key influencing factors and market inclinations, in addition to the relevant market segments and sub-segments.

Analytical Tools: The Global Animal Stem Cell Therapy Market report consists of the precisely studied and evaluated information of the key players and their market scope using several analytical tools, including SWOT analysis, Porters five forces analysis, investment return analysis, and feasibility study. These tools have been used to efficiently study the growth of major industry participants.

Potential Customers: The report offers detailed insights to users, service providers, suppliers, manufacturers, stockholders, and individuals who are interested in evaluating and self-studying this market.

Inquiry for Buying Report: http://www.intenseresearch.com/market-analysis/global-animal-stem-cell-therapy-market-2019-by.html#inquiry-for-buying

Conclusively, the report helps a reader to get an absolute understanding of the Animal Stem Cell Therapy industry through details about the market projection, competitive scenario, industry environment, growth constraining factors, limitations, entry barriers, the provincial regulatory framework as well as upcoming market investment and opportunities, challenges and other growth-promoting factors. This report will provide you a clear view of each and every facet of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Sorry! The Author has not filled his profile.

Original post:
Global Animal Stem Cell Therapy Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry PressRelease

Global Canine Stem Cell Therapy Market 2019-2025 Industry Perspective, Comprehensive Analysis by VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus,…

Heres latest informative report on the worldwide Canine Stem Cell Therapy Market 2019-2025 which has been added to our humongous database. The Canine Stem Cell Therapy market research report will help you to shape the future of your businesses by developing well-informed business-oriented decisions. Furthermore, the report on Canine Stem Cell Therapy market provides a comprehensive analysis of several industrial aspects such as size, recent technological techniques, new innovations, market shares, and global Canine Stem Cell Therapy market trends.

Request For Free Sample Report Of Canine Stem Cell Therapy Market Report: https://marketsresearch.biz/report/global-canine-stem-cell-therapy-market-307023#request-sample

Besides this, the analytical information about the Canine Stem Cell Therapy market has been compiled through data exploratory methods such as primary as well as secondary research techniques. Moreover, our expert team throws light on several static and dynamic elements of the worldwide Canine Stem Cell Therapy market.

This study highlights numerous top key players in order to get better insights into universal businesses. It also provides a brief description of the top-level companies which are operating in the different regions of the world. The study report on Canine Stem Cell Therapy market includes significant data regarding the enterprise overview, contact details, and other crucial strategies followed by the competitive Canine Stem Cell Therapy market vendors. The global Canine Stem Cell Therapy market report is the systematic and accurate documentation of several business perspectives including major geographies, opportunities, restraints, challenges, and drivers. The Canine Stem Cell Therapy market report has been aggregated as per the several market segments as well as sub-segments associated with the worldwide industry.

Checkout Inquiry For Buying or Customization of Report: https://marketsresearch.biz/report/global-canine-stem-cell-therapy-market-307023#inquiry-for-buying

Region-wise analysis of the Canine Stem Cell Therapy market as follows:

Geographically, the worldwide Canine Stem Cell Therapy market has been studied in several regions such as Latin America, Asia-Pacific, Europe, North America, India, the Middle East, and Africa. Reportedly, the global Canine Stem Cell Therapy region is dominating this industry in the forthcoming year.

Major Canine Stem Cell Therapy market players included in this market are:

VETSTEM BIOPHARMACell Therapy SciencesRegeneusAratana TherapeuticsMedivet BiologicsOkyanosVetbiologicsVetMatrixMagellan Stem CellsANIMAL CELL THERAPIESStemcellvet

Global Canine Stem Cell Therapy Market segmentation: By Product Type Analysis

Allogeneic Stem CellsAutologous Stem cells

Global Canine Stem Cell Therapy Market segmentation: By Application

Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes

Access Report Description, Table Of Content of Canine Stem Cell Therapy Market Report https://marketsresearch.biz/report/global-canine-stem-cell-therapy-market-307023

The study figures out how certain account threats and challenges can act as a problematic factor for the business. The evaluation of the Canine Stem Cell Therapy market covers various aspects related to the social, economical, technological and political environment that adds flexibility to the overall research. In addition to this, the Canine Stem Cell Therapy market study generates real-time statistics on vital components such as gross margin, growth prospects, sales and profits to displays substantial business growth in upcoming years.

Apart from exploring the company profiles of key market leaders, the research study on Canine Stem Cell Therapy market collects and meanwhile, analyzes raw information on the import/export status, supply chain management, regulatory framework, and cost structure that is anticipated to articulate the trajectory of the Canine Stem Cell Therapy industry landscape. In this research, the analysts have used the market-leading assessment tools to explain the growing level of competition, product launches, new participants, recent acquisition and mergers.

Read the rest here:
Global Canine Stem Cell Therapy Market 2019-2025 Industry Perspective, Comprehensive Analysis by VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus,...

Next level giving: A piece of your heart can literally save lives – NWAOnline

Many of us look for ways to give back during the holidays as a chance to demonstrate gratitude for what we have by helping others who might not be so fortunate. Northwest Arkansas is chock full of wonderful nonprofit organizations that can always use a helping hand, but if you're looking for a way to kick your giving up a notch, consider these three organizations for a chance to -- literally -- give a piece of yourself to save someone else's life.

Community Blood Center of the Ozarks

3503 S. Thompson, Springdale, (479) 927-1200

1400 SE Walton Blvd., Bentonville, (479) 464-2506

"There are 12 hospitals in Northwest Arkansas that use blood that comes from our center and nowhere else," says Community Blood Center of the Ozarks Marketing Manager Chris Pilgrim. "And over 40 hospitals from southwest Missouri and Northwest Arkansas, combined."

Donating blood is one of the easiest ways to save someone's life, says Pilgrim, but only a small percentage of the population actively participates. Out of the 37% of Americans who are eligible, only 10% actually give.

"You would think that a fear of needles would be the No. 1 reason people don't give blood -- and while that's pretty significant, it's not the biggest reason," he says. "The biggest is just that people have never been asked. It's kind of something that goes on in the background. It takes a conscious decision for 200 people a day to donate blood and keep things going here."

If aversion to needles is your issue, fear not, says Pilgrim.

"If you're scared of needles, it doesn't hurt very much -- it's a slight sting, and the needle is in your arm for maybe 10 minutes," he says. "When you're finished with your donation, you walk out. It's that easy. It doesn't take much time or any money, but it has a real impact on someone's life. That's the biggest gift you can give, when you save lives."

And each donation, says Pilgrim, saves multiple lives.

"We used to say that one donation could save three lives, because we divided it up into red blood cells, platelets and plasma, but your blood donation could get divided up and go with lots of people -- the more you give, the more you multiply."

While all blood donations are valued in order to keep the area hospitals fully stocked, Pilgrim says that some blood types are a lot more in demand than others.

"There are a couple of specific blood products that we look for," says Pilgrim. "First of all, when you're talking about red blood cells, O Negative is a universal type. Even though only 6% of the population is Type O Negative, it's used more than its fair share in trauma cases when you can't readily type a victim. The other universal is AB plasma -- it can be given to anybody."

You can give blood at any of the center's locations -- there are also two Missouri locations -- and it's suggested that you first make an appointment online to expedite your visit. Pilgrim says the bulk of the donations, however, are collected at blood drives.

"The vast majority of the blood we collect comes from places where we take our show on the road -- churches, schools, businesses," he explains. "If you have a business that wants to hold a blood drive, please give us a call. We can take you through the steps and help make it as painless and rewarding as possible."

Project Zero

theprojectzero.org

Tiphanie Gurwell, Northwest Arkansas outreach coordinator for the nonprofit organization Project Zero, says there are hundreds of children in Arkansas who are waiting to be adopted -- and it's her organization's goal to find each and every one of those children a home. Project Zero, according to its mission statement, will "diligently and enthusiastically promote adoption through the foster care system with the ultimate goal of finding a forever family for every child that is waiting."

Project Zero works specifically with a group of children who might be harder to place, says Gurwell.

"A lot of these kids are part of a sibling group, or they have special needs, or they're teenagers," she says. "So they're what we would consider the harder-to-place kids. When most people go into adoption, they want younger kids; that number doesn't take into consideration the kids that are having their parental rights terminated but are getting adopted quickly. We generally don't advocate for a child under the age of 5 unless they're in a sibling group or have a special need."

Gurwell says one of the ways the organization seeks to connect potential adoptive parents with children are its private events where children and adults mix and mingle and get to know each other, like the one coming up in Little Rock.

"Seventy-nine percent of the kids [in state care] will attend this event," says Gurwell. "They'll come and get Christmas presents and play fun games, all while interacting with families who are looking to adopt. They may connect in a way they don't just by looking at a photo on the internet. It's kind of a game changer, because you get that one opportunity, and it's no longer just a picture or a number -- you get to meet with and talk to the child."

Even one visit to the organization's website is enough to personalize its mission: It maintains a "Heart Gallery," a collection of pictures, biographies and, sometimes, videos of the children for whom they're advocating. The photos show smiling, hopeful faces, and the biographies are heartbreakingly forthright about the trauma the child might have endured and the special needs that resulted. But they also give insight into each child's particular personality and their hopes and dreams for their futures.

"I really didn't have a family in my past, and I would like to start over and build a new life in a new family that loves me, and I love them, and that cares about me and loves me and understands what I've been going through," says Andreka, a teenager, in a short video. Though the teenagers in the Heart Gallery may be aging out of the system soon, their need for a permanent placement is still great, says Gurwell.

"Typically, the kids that age out of foster care don't end up doing the best," explains Gurwell. "If you grew up your whole life, and no one ever taught you how to budget, how to pay a bill, how to apply for a loan, how to apply for college -- what ends up happening is that, at the age of 18 or 21, they age out with very little knowledge. [The Division of Children and Family Services] does the best they can do, given their resources, but when you get out in the real world, and you're working a minimum wage job, you're trying to go to college and there's no one to ask for help? The statistics show they're likely to end up in the same situation that they were removed from. A lot of them will end up in jail or homeless.

"I think it's important for people to get these kind of negative stereotypes out of their head -- like, they're going to come into my house angry, or they don't want to be adopted. There are a million different excuses people have when talking about teens, but I've had the opportunity to meet a lot of our teens, and they do want to be adopted. They want to be loved. Even if it's a short period -- let's say you adopt at 16 or 17 years old. Those two years can be a game changer. They've got someone to come home to. It may be a minimum time in your home, but it's a lifetime commitment to that child."

Gurwell says there's no one profile of a family that would make good adoptive parents.

"Every child has a different story," she says. "Some kids need a single mother because of their trauma. Some kids need a two-parent family or need to be the only child or youngest child in the home. Each case is so unique. I would say the only thing we wish for in our families is, obviously, that they be able to support the child financially without government assistance. From our organization's perspective, we want families who are open-minded, we want families who aren't going to come in and say, 'I want a kid 5 and under.' We want families who say, 'We are called to do this, but we don't know what it looks like, so let's just roll with it and see what happens.' I think sometimes when we put barriers up of what we don't want, it limits the connections you might make with someone you might not even think about looking at -- but then you meet a child, and it's a game changer."

For those interested in exploring the possibilities of adoption, the Project Zero website is a great place to start and can explain what the next steps in the process would be.

Be the Match

Bethematch.org

(800) MARROW-2

When Bill Brashear got the news that his son was diagnosed with acute lymphoblastic leukemia, it was a shock: His son was a healthy young man in the prime of his life who had never experienced previous health issues.

"It was gut wrenching," he says. "It was horrible. But the wonderful thing that came out of it was [our knowledge of] Be the Match."

Early on in his treatment, Brashear's son needed a blood stem cell transplant; fortunately, a match was found within his family. But when he needed another one later on, the family turned to the international donor database Be the Match.

"They did a search for [my son's] DNA makeup and didn't find a match in anyone in the United States but found a young man in Germany," says Brashear. "They harvested this person's blood cells in Germany, a courier was there, got the blood cells that he had donated, flew back to the United States, and the next day, they were infused in [my son]."

Clifford Ackerman now works with the organization as a patient and lead liaison, but his first introduction to Be the Match was as a patient when he was diagnosed with non-Hodgkin's lymphoma.

"I had two sisters and a fraternal twin, and nobody matched me," he says. "I found a match through Be the Match, and now I have a blood brother who saved my life by joining the registry eight years before to help someone in his community. We just celebrated Thanksgiving -- if you want to show how thankful you are for what you have, this is a wonderful way."

Be the Match collects donations in three areas: peripheral blood stem cells (PBSC), marrow and umbilical cord blood. These donations can be used to help treat 70 different blood diseases and cancers. Be the Match facilitated nearly 6,200 transplants in 2018. But with nearly 70 percent of patients requiring transplants outside their friends and family group, new donors are always needed.

"It's very similar to donating plasma platelets," Ackerman explains of the outpatient process, which is open to donors ages 18 to 44. "Nothing is completely painless -- there's always a small discomfort to save a life. With this process, it's either a bit of achiness before or after the process. It's not like what you see on Grey's Anatomy or ER or House -- you don't feel pain or discomfort during, but maybe some achiness afterward."

Most matches are found by people who match the patient's ethnic background, and the likelihood of a patient finding a match in the system ranges from 77% for white patients, 57% for American Indian and Alaska Native patients, 46% for Hispanic or Latino patients, 41% for Asian or Pacific Islander patients and 23% for African-American patients.

The entire process, from the initial medical exam to determine eligibility through the donation procedure, usually takes around 30 hours, says Ackerman, and is entirely free for the donor -- it's either paid for by the patient's insurance or by Be the Match.

"We pay for the travel, the meals and even for one companion," says Ackerman. "Even tolls, mileage, day care -- even pet care. If they come up to us and say, 'Hey, I started a new job or ran out of paid time off', we'll even cover their wages."

Ackerman says a young man named Blee, a 2014 graduate from Pulaski Academy in Little Rock, is currently looking for a matching donor to help treat his aplastic anemia. To start the process to see if you're a match for Belee -- or another patient currently waiting on a donor -- scan the QR code pictured with this story or text NWADG4aCure to 61474. Ackerman says the initial screening is simple and fast, and a swab kit can be mailed to your home address quickly.

"Be the Match is such a big deal," says Brashear. "It saved [my son's] life, and it's saved other people's lives, but we don't hear enough about it. That's why I'm shouting from the rooftops and ringing the bells and whatever else to get the word out -- because it might save somebody's life, for sure."

Courtesy Photo The Heart Gallery on the Project Zero website is a great place to find out more information about the children in the foster care system who are seeking permanent homes in Arkansas -- like Jawaun.

Courtesy Photo The Heart Gallery on the Project Zero website is a great place to find out more information about the children in the foster care system who are seeking permanent homes in Arkansas -- like Jawaun.

NWA Democrat-Gazette/CHARLIE KAIJO Community Blood Center of the Ozarks' Chris Pilgrim says the majority of the blood donations the organization collects come from community-organized blood drives like this one at Rogers High School in November. Contact the CBCO if or your organization would like to host a blood drive.

NAN Our Town on 12/05/2019

Link:
Next level giving: A piece of your heart can literally save lives - NWAOnline

Back to Top